Bio-Thera Launches Adalimumab In China

Qletli Biosimilar Is First Chinese Humira Rival

Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.

First
Qletli is Bio-Thera’s First Launch, The Firm's First Approved Biosimilar And The First Chinese Rival To Humira • Source: Shutterstock

Bio-Thera Solutions has celebrated several firsts with the introduction of its Qletli (adalimumab) biosimilar in China. Not only does the product represent Bio-Thera’s first commercial launch, but it is also the first and only biosimilar rival to AbbVie’s Humira brand to have been approved by China’s National Medical Products Administration, Bio-Thera’s first biosimilar to receive approval, and only the second biosimilar to have been approved by the NMPA overall.

“The commercial launch of Bio-Thera’s first approved product is an enormous milestone for the company,” said CEO Shengfeng Li. “It...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin